CMPX vs. ALVR, ABOS, SCLX, ALVO, ZURA, VIGL, HUMA, PSTX, IPHA, and MESO
Should you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include AlloVir (ALVR), Acumen Pharmaceuticals (ABOS), Scilex (SCLX), Alvotech (ALVO), Zura Bio (ZURA), Vigil Neuroscience (VIGL), Humacyte (HUMA), Poseida Therapeutics (PSTX), Innate Pharma (IPHA), and Mesoblast (MESO). These companies are all part of the "biological products, except diagnostic" industry.
Compass Therapeutics (NASDAQ:CMPX) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation, community ranking and profitability.
AlloVir received 7 more outperform votes than Compass Therapeutics when rated by MarketBeat users. However, 68.97% of users gave Compass Therapeutics an outperform vote while only 64.29% of users gave AlloVir an outperform vote.
Compass Therapeutics is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.
Compass Therapeutics has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.
In the previous week, Compass Therapeutics had 1 more articles in the media than AlloVir. MarketBeat recorded 3 mentions for Compass Therapeutics and 2 mentions for AlloVir. Compass Therapeutics' average media sentiment score of 0.64 beat AlloVir's score of 0.29 indicating that Compass Therapeutics is being referred to more favorably in the media.
71.0% of Compass Therapeutics shares are held by institutional investors. Comparatively, 47.4% of AlloVir shares are held by institutional investors. 30.0% of Compass Therapeutics shares are held by insiders. Comparatively, 40.0% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Compass Therapeutics' return on equity of -26.62% beat AlloVir's return on equity.
Compass Therapeutics presently has a consensus target price of $9.05, indicating a potential upside of 376.32%. AlloVir has a consensus target price of $18.75, indicating a potential upside of 814.63%. Given AlloVir's higher probable upside, analysts clearly believe AlloVir is more favorable than Compass Therapeutics.
Summary
Compass Therapeutics beats AlloVir on 10 of the 14 factors compared between the two stocks.
Get Compass Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Compass Therapeutics Competitors List
Related Companies and Tools